Arrowhead Pharmaceuticals, Inc.
ARWR
$65.09
$0.020.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 86.45% | -147.31% | 314.02% | -1.49% | 0.15% |
| Total Depreciation and Amortization | 2.62% | 2.28% | 16.22% | 4.18% | 5.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 136.27% | -15.11% | 30.95% | 42.64% | -21.60% |
| Change in Net Operating Assets | -113.59% | -139.45% | 711.90% | -193.56% | -67.73% |
| Cash from Operations | 113.24% | -133.63% | 414.52% | -6.60% | -18.89% |
| Capital Expenditure | -216.79% | 55.37% | 29.52% | 69.06% | -68.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.27% | 134.65% | -591.46% | 142.50% | -1,028.28% |
| Cash from Investing | -48.64% | 133.65% | -646.37% | 134.50% | -3,307.99% |
| Total Debt Issued | -55.45% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 67.02% | -- | -- | -- |
| Issuance of Common Stock | 127.35% | -99.91% | 38,386.91% | 184.30% | -42.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | 738.16% | -106.27% |
| Cash from Financing | 108.60% | -146.20% | 347.72% | -94.70% | 672.20% |
| Foreign Exchange rate Adjustments | -125.81% | 123.13% | -491.18% | -101.57% | 2,044.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 273.04% | -142.42% | 370.15% | -246.60% | 157.09% |